Valneva Reports H1 2026 Product Sales Of €64.0M Down From €91.0M YoY, Net Loss Widens To €63.3M From €20.8M YoY
- Total product sales of €64.0 million
- In-line with expectations; full-year guidance of €135 -150 million reaffirmed
- Solid cash position of €121.5 million as of end June 2026
- Reflects disciplined cash management and proceeds from the recent reserved offering1
- Restructuring program implemented with positive P&L and cash flow impacts expected in the second half of the year and beyond
- Regulatory decisions for Lyme disease vaccine candidate expected in the next twelve months2
- Pfizer remains optimistic about obtaining registration for the vaccine candidate3
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。